FDA extends review period for Incyte’s GVHD treatment Jakafi

This article was originally published here

The 24 May is the new Prescription Drug User Fee Act (PDUFA) target action date for Jakafi, which is the treatment for patients with GVHD who have had

The post FDA extends review period for Incyte’s GVHD treatment Jakafi appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply